Literature DB >> 30889382

Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.

Shivani Srivastava1, Alexander I Salter2, Denny Liggitt3, Sushma Yechan-Gunja2, Megha Sarvothama2, Kirsten Cooper2, Kimberly S Smythe2, Jarrod A Dudakov4, Robert H Pierce2, Christoph Rader5, Stanley R Riddell6.   

Abstract

Many potential targets for CAR-T cells in solid tumors are expressed in some normal tissues, raising concern for off-tumor toxicity. Following lymphodepletion, CAR-T cells targeting the tumor-associated antigen ROR1 lysed tumors in mice but induced lethal bone marrow failure due to recognition of ROR1+ stromal cells. To improve selectivity, we engineered T cells with synthetic Notch (synNotch) receptors specific for EpCAM or B7-H3, which are expressed on ROR1+ tumor cells but not ROR1+ stromal cells. SynNotch receptors induced ROR1 CAR expression selectively within the tumor, resulting in tumor regression without toxicity when tumor cells were segregated from, but not when co-localized with, normal ROR1+ cells. This strategy, thus, permits safe targeting of tumors that are sufficiently separated from normal cells.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B7-H3; ROR1; T cells; chimeric antigen receptor; combinatorial antigen recognition; immunotherapy; logic gating; mesenchymal stem cell; synthetic Notch receptors; toxicity

Mesh:

Substances:

Year:  2019        PMID: 30889382      PMCID: PMC6450658          DOI: 10.1016/j.ccell.2019.02.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  37 in total

Review 1.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

3.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

4.  Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Authors:  Carolina Berger; Daniel Sommermeyer; Michael Hudecek; Michael Berger; Ashwini Balakrishnan; Paulina J Paszkiewicz; Paula L Kosasih; Christoph Rader; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-10-29       Impact factor: 11.151

Review 5.  Regulation of hematopoietic stem cells by bone marrow stromal cells.

Authors:  Bryan A Anthony; Daniel C Link
Journal:  Trends Immunol       Date:  2013-11-05       Impact factor: 16.687

6.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.

Authors:  Zakaria Grada; Meenakshi Hegde; Tiara Byrd; Donald R Shaffer; Alexia Ghazi; Vita S Brawley; Amanda Corder; Kurt Schönfeld; Joachim Koch; Gianpietro Dotti; Helen E Heslop; Stephen Gottschalk; Winfried S Wels; Matthew L Baker; Nabil Ahmed
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-09       Impact factor: 10.183

7.  Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

Authors:  Jiahui Yang; Sivasubramanian Baskar; Ka Yin Kwong; Michael G Kennedy; Adrian Wiestner; Christoph Rader
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

8.  ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.

Authors:  Yu-Zhu Zheng; Rui Ma; Jian-Kang Zhou; Cheng-Lin Guo; Yong-Sheng Wang; Zheng-Guang Li; Lun-Xu Liu; Yong Peng
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

9.  Stromal Cell Subsets Directing Neonatal Spleen Regeneration.

Authors:  Jonathan K H Tan; Takeshi Watanabe
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

10.  A perisinusoidal niche for extramedullary haematopoiesis in the spleen.

Authors:  Christopher N Inra; Bo O Zhou; Melih Acar; Malea M Murphy; James Richardson; Zhiyu Zhao; Sean J Morrison
Journal:  Nature       Date:  2015-11-16       Impact factor: 49.962

View more
  82 in total

Review 1.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

Review 2.  Immune-Based Therapies in Acute Leukemia.

Authors:  Matthew T Witkowski; Audrey Lasry; William L Carroll; Iannis Aifantis
Journal:  Trends Cancer       Date:  2019-08-29

3.  Designed protein logic to target cells with precise combinations of surface antigens.

Authors:  Marc J Lajoie; Scott E Boyken; Alexander I Salter; Jilliane Bruffey; Anusha Rajan; Robert A Langan; Audrey Olshefsky; Vishaka Muhunthan; Matthew J Bick; Mesfin Gewe; Alfredo Quijano-Rubio; JayLee Johnson; Garreck Lenz; Alisha Nguyen; Suzie Pun; Colin E Correnti; Stanley R Riddell; David Baker
Journal:  Science       Date:  2020-08-20       Impact factor: 47.728

Review 4.  Multispecific drugs herald a new era of biopharmaceutical innovation.

Authors:  Raymond J Deshaies
Journal:  Nature       Date:  2020-04-15       Impact factor: 49.962

Review 5.  Developing neoantigen-targeted T cell-based treatments for solid tumors.

Authors:  Tori N Yamamoto; Rigel J Kishton; Nicholas P Restifo
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

Review 6.  Industrializing engineered autologous T cells as medicines for solid tumours.

Authors:  Cedrik M Britten; Aiman Shalabi; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2021-04-08       Impact factor: 84.694

Review 7.  CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.

Authors:  Salvatore Fiorenza; Cameron J Turtle
Journal:  BioDrugs       Date:  2021-04-07       Impact factor: 5.807

8.  Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.

Authors:  Ruth Dannenfelser; Gregory M Allen; Benjamin VanderSluis; Ashley K Koegel; Sarah Levinson; Sierra R Stark; Vicky Yao; Alicja Tadych; Olga G Troyanskaya; Wendell A Lim
Journal:  Cell Syst       Date:  2020-09-10       Impact factor: 10.304

Review 9.  Gene editing for immune cell therapies.

Authors:  Stefanie R Bailey; Marcela V Maus
Journal:  Nat Biotechnol       Date:  2019-06-03       Impact factor: 54.908

Review 10.  The Emerging Landscape of Immune Cell Therapies.

Authors:  Evan W Weber; Marcela V Maus; Crystal L Mackall
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.